Wednesday, March 13, 2019 11:08:57 AM
March 12, 2019
Tags: NewsPoints Osiris Smith & Nephew United States Corporate Affairs Mergers &
Acquisitions
A group of Osiris Therapeutics Inc. shareholders are attempting
to block the $660.5 million purchase of the company by Smith & Nephew plc.
The shareholders allege that the purchase price of $19 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. In addition, shareholders allege that Osiris senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.
Osiris Therapeutics did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Osiris Therapeutics for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or contact@tripplevy.com
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM